Abstract
A 40-year premenopausal woman was referred by her treating oncologist for F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to rule out disease recurrence or metastasis. She had completed therapy for Hodgkin lymphoma (Stage IIA) 1 year earlier. Post-therapy gallium-67 study showed no evidence of residual disease and the patient was on regular follow-up. The only abnormality detected on the FDG-PET/CT study was a focus of abnormal FDG accumulation in the pelvis, suprapubically. Fused PET-CT localized the uptake to the uterine myometrium in the fundal region posteriorly corresponding to mild inhomogeneity in attenuation with a bulky uterus on CT. MRI of the pelvis confirmed the presence of a uterine leiomyoma in the fundal region. The patient was put on danazol (200 mg twice daily for 14 days) and a repeat PET-CT of the pelvis was done after 14 days, which revealed complete disappearance of FDG uptake in the leiomyoma. This proved that F-18 FDG uptake in the leiomyoma was probably related to its vascularity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 452-455 |
| Number of pages | 4 |
| Journal | Clinical nuclear medicine |
| Volume | 34 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2009 |
| Externally published | Yes |
Keywords
- Danazol
- F-18 FDG
- Leiomyoma
- PET/CT
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Suppression of F-18 fluorodeoxyglucose uptake in benign uterine leiomyomas with danazol'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS